The presence of cerebellar signs including ataxic gait and slurred speech combined with hyperreflexia and cognitive clouding represents the most critical assessment finding

Because these neurotoxic manifestations do not occur at therapeutic lithium levels and indicate central nervous system toxicity requiring urgent intervention. At therapeutic concentrations, lithium may produce fine tremor, mild polyuria, and gastrointestinal symptoms, but it does not cause cerebellar dysfunction, dysarthria, or hyperreflexia. The emergence of these neurological findings marks the transition from tolerable side effects to neurotoxicity and indicates lithium levels have risen to a dangerous range. The recent addition of hydrochlorothiazide is the likely precipitant, as thiazide diuretics reduce renal lithium clearance by 25-40% through enhanced proximal tubular reabsorption.

The coarse tremor is the primary differentiating finding

Because lithium at therapeutic levels produces only a fine postural tremor, and the progression from fine to coarse tremor is the earliest and most sensitive clinical indicator that lithium levels have exceeded the therapeutic range. While the other findings contribute to the clinical picture, the tremor quality change from fine to coarse is the single most reliable clinical marker for emerging lithium toxicity. Coarse tremor appears before any other neurological signs and serves as the sentinel finding that should prompt immediate level assessment. In patients on stable lithium therapy, any change in tremor character should be considered toxicity until proven otherwise.

The fatigue and nausea are the most critical distinguishing features

Because these gastrointestinal and constitutional symptoms do not occur at therapeutic lithium levels and their presence automatically indicates toxicity. Lithium at therapeutic levels is well-tolerated without any gastrointestinal effects, so the appearance of nausea in a previously stable patient confirms that levels have risen above the therapeutic range. The addition of hydrochlorothiazide is relevant only as a potential contributor to dehydration-related fatigue rather than as a direct cause of elevated lithium levels. Checking a serum lithium level is unnecessary when these clinical symptoms are present because they are pathognomonic for toxicity.

The disorientation to date is the most critical finding

Because any degree of cognitive impairment in a patient taking lithium constitutes a medical emergency requiring immediate hemodialysis. Lithium at therapeutic levels has no effect on cognitive function, and orientation testing is the most sensitive screening tool for lithium toxicity. Temporal disorientation specifically indicates lithium accumulation in the hippocampal formation and temporal lobes and predicts imminent seizure activity. The other findings including tremor, ataxia, and nausea are common side effects that do not independently suggest toxicity. Cognitive testing should be the primary monitoring tool for all patients on lithium maintenance therapy. While disorientation is a concerning finding in lithium toxicity, several assertions in this option are incorrect.